Garbe C - Search Results

1

Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?

Martens A, Zelba H, Garbe C, Pawelec G, Weide B. Martens A, et al. Among authors: garbe c. Oncoimmunology. 2014 Jan 1;3(1):e27845. doi: 10.4161/onci.27845. Epub 2014 Feb 14. Oncoimmunology. 2014. PMID: 24800171 Free PMC article.

2

Imiquimod in the treatment of extensive recurrent lentigo maligna.

Kamin A, Eigentler TK, Radny P, Bauer J, Weide B, Garbe C. Kamin A, et al. Among authors: garbe c. J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):51-2. doi: 10.1016/j.jaad.2004.07.047. J Am Acad Dermatol. 2005. PMID: 15692515

3

[Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].

Eigentler TK, Radny P, Kamin A, Weide B, Caroli UM, Garbe C. Eigentler TK, et al. Among authors: garbe c. J Dtsch Dermatol Ges. 2005 Aug;3(8):592-8. doi: 10.1111/j.1610-0387.2005.05051.x. J Dtsch Dermatol Ges. 2005. PMID: 16033477 Review. German.

4

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

Carralot JP, Weide B, Schoor O, Probst J, Scheel B, Teufel R, Hoerr I, Garbe C, Rammensee HG, Pascolo S. Carralot JP, et al. Among authors: garbe c. Genet Vaccines Ther. 2005 Aug 22;3:6. doi: 10.1186/1479-0556-3-6. Genet Vaccines Ther. 2005. PMID: 16115316 Free PMC article.

5

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.

Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, Radny P, Garbe C. Eigentler TK, et al. Among authors: garbe c. J Am Acad Dermatol. 2007 Oct;57(4):616-21. doi: 10.1016/j.jaad.2007.05.022. Epub 2007 Jul 3. J Am Acad Dermatol. 2007. PMID: 17610993 Clinical Trial.

6

Plasmid DNA- and messenger RNA-based anti-cancer vaccination.

Weide B, Garbe C, Rammensee HG, Pascolo S. Weide B, et al. Among authors: garbe c. Immunol Lett. 2008 Jan 15;115(1):33-42. doi: 10.1016/j.imlet.2007.09.012. Epub 2007 Oct 26. Immunol Lett. 2008. PMID: 18006079 Review.

7

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.

Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S. Weide B, et al. Among authors: garbe c. J Immunother. 2008 Feb-Mar;31(2):180-8. doi: 10.1097/CJI.0b013e31815ce501. J Immunother. 2008. PMID: 18481387 Clinical Trial.

8

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.

Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Weide B, et al. Among authors: garbe c. J Immunother. 2009 Jun;32(5):498-507. doi: 10.1097/CJI.0b013e3181a00068. J Immunother. 2009. PMID: 19609242 Clinical Trial.

9

Melanoma staging: facts and controversies.

Forschner A, Eigentler TK, Pflugfelder A, Leiter U, Weide B, Held L, Meier F, Garbe C. Forschner A, et al. Among authors: garbe c. Clin Dermatol. 2010 May-Jun;28(3):275-80. doi: 10.1016/j.clindermatol.2009.06.012. Clin Dermatol. 2010. PMID: 20541679

10

Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies.

Leiter U, Eigentler TK, Forschner A, Pflugfelder A, Weide B, Held L, Meier F, Garbe C. Leiter U, et al. Among authors: garbe c. Clin Dermatol. 2010 May-Jun;28(3):311-5. doi: 10.1016/j.clindermatol.2009.10.001. Clin Dermatol. 2010. PMID: 20541684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

802 results

Search Page

Filters